Intellia Therapeutics Inc (NASDAQ:NTLA)

82.62
Delayed Data
As of Jan 20
 -1.05 / -1.25%
Today’s Change
43.86
Today|||52-Week Range
202.73
-30.13%
Year-to-Date
Editas (EDIT) Focuses on Developing Gene-Editing Eye Drug
Jan 19 / Zacks.com - Paid Partner Content
Is Beam Therapeutics a Good Stock to Buy Now?
Jan 16 / MotleyFool.com - Paid Partner Content
5 Charts to Remember if the Stock Market Crashes in 2022
Jan 19 / MotleyFool.com - Paid Partner Content
"Motley Fool Money" 2022 Investing Preview
Jan 07 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close83.67
Today’s open84.55
Day’s range82.01 - 89.75
Volume1,182,474
Average volume (3 months)791,556
Market cap$6.8B
Data as of 4:34pm ET, 01/20/2022

Growth & Valuation

Earnings growth (last year)-13.81%
Earnings growth (this year)-49.62%
Earnings growth (next 5 years)+3.00%
Revenue growth (last year)+34.55%
P/E ratioNM
Price/Sales52.52
Price/Book11.49

Competitors

----
ARWRArrowhead Pharmaceut...-1.28-2.38%
NBIXNeurocrine Bioscienc...-0.03-0.04%
NVAXNovavax Inc-1.97-2.13%
Data as of 5:06pm ET, 01/20/2022

Financials

Next reporting dateMarch 16, 2022
EPS forecast (this quarter)-$0.94
Annual revenue (last year)$58.0M
Annual profit (last year)-$134.2M
Net profit margin-231.46%

Profile

Sector
Health Technology
Industry
Biotechnology
No executives to display
Corporate headquarters
Cambridge, Massachusetts

Forecasts